Last reviewed · How we verify

Artemether-lumefantrine combination plus albendazole

Navrongo Health Research Centre, Ghana · FDA-approved active Small molecule

This combination kills malaria parasites through artemether's rapid parasite clearance and lumefantrine's sustained blood schizonticide activity, while albendazole eliminates co-occurring helminth infections.

This combination kills malaria parasites through artemether's rapid parasite clearance and lumefantrine's sustained blood schizonticide activity, while albendazole eliminates co-occurring helminth infections. Used for Uncomplicated malaria (Plasmodium falciparum) with concurrent helminth infection, Malaria and soil-transmitted helminth co-infections in endemic regions.

At a glance

Generic nameArtemether-lumefantrine combination plus albendazole
SponsorNavrongo Health Research Centre, Ghana
Drug classAntimalarial combination with anthelmintic
TargetPlasmodium falciparum (multiple mechanisms); Ascaris, Hookworm, Trichuris (tubulin)
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Artemether is a fast-acting artemisinin derivative that rapidly reduces parasite biomass by generating reactive oxygen species within infected red blood cells. Lumefantrine provides sustained antimalarial activity by inhibiting parasite heme polymerization. Albendazole is a broad-spectrum anthelmintic that disrupts microtubule formation in helminths, addressing the common co-infection of malaria and intestinal worms in endemic populations.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: